As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: June 15, 2013
by Pharma Biz:
Eli Lilly and Company has stopped phase II study (BACC) for LY2886721, a beta secretase (BACE) inhibitor being investigated as a once daily treatment for its potential to slow the progression of Alzheimer’s disease. The decision to terminate the study was due to abnormal liver biochemical tests. Clinical study investigators have been notified.
“While stopping this phase II study for our BACE inhibitor is disappointing, patient safety is of utmost importance to Lilly,” said Jan M Lundberg, executive vice president, science and technology, and president, Lilly Research Laboratories. “Discovering and developing medicines for devastating diseases like Alzheimer’s is fraught with many challenges, but Lilly’s 25-year commitment to bringing medicines to the millions of Alzheimer’s disease patients who are waiting will not wane.”
The cases of abnormal liver biochemical tests were identified as part of routine monitoring. Lilly will continue to monitor all participants with abnormal liver biochemical tests.
Based on the information Lilly has today, it believes that the abnormal liver biochemical tests observed in this study are not related to the BACE mechanism and continues to be interested in developing BACE inhibitors for the benefit of patients with Alzheimer’s disease. Lilly will further evaluate this data prior to determining next steps for the entire LY2886721 clinical development programme.
The company expects to incur a financial charge associated with the decision to stop this trial. However, the amount of this charge is not expected to be material and is not expected to result in a change to the company’s previously-issued 2013 financial guidance.
Lilly currently has eight potential new medicines in its clinical development pipeline being evaluated to treat neuroscience-related diseases and disorders, including: schizophrenia, Alzheimer’s disease, depression, bipolar disorder, migraine prevention and osteoarthritis pain. Of the eight potential new medicines, two are currently in Phase III clinical development — edivoxetine and solanezumab.
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations.
The emerging science of epigenetics describes the way our lifestyle and environment influence our gene expression over time. This growing field of research is a hot topic right now because it has radically altered our...
They cleansed the rodents of retired cells. Over...
In 2012, almost one-third of the Canadian population provided care to family members or friends with long-term health conditions, primarily those linked to aging/frailty and forms of dementia. This number will only increase, placing more and...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.